Hepatitis A transmission by factor IX concentrates

Vox Sanguinis

Volumn 71, Issue 2, 1996, Pages 126-128

  Lawlor, E ^a,d,e   Graham, S ^b   Davidson, F ^b   Yap, P L ^b   Cunningham, C ^a   Daly, H ^c   Temperley, I J ^c,d  

^a IRISH BLOOD TRANSFUSION SERVICE   (Ireland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e Pelican House   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9 CONCENTRATE; HEPATITIS A ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; VIRUS RNA;

ADULT; ARTICLE; CASE REPORT; DRUG SAFETY; HEMOPHILIA B; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; JAUNDICE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0029823380     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1996.7120126.x     Document Type: Article

References (17)

1. Geraty RJ, Aronson DL: Plasma derivatives and viral hepatitis. Transfusion 1982;22:347-351.
2. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU, Purcell RH, and the Italian Collaborative Group: Transmission of hepatitis A to patients with haemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994;120:1-7.
3. Johnson Z, Thornton L, Tobin A, Lawlor E, Power J, Hillary I, Temperley I: An outbreak of hepatitis A among Irish haemophiliacs. Int J Epidemiol 1995;24:821-828.
4. Gerritzen A, Schneweis KE, Brackmann HH, Oldenburg J, Hanfland P, Gerlich WH, Caspari G: Acute hepatitis A in haemophiliacs. Lancet 1992;340:1231-1232.
5. Peerlinck K, Vermylen J: Acute hepatitis A in patients with haemophilia A. Lancet 1993;341: 179.
6. Kedda MA, Kew MC, Cohn RJ, Field SP, Schwyzer R, Song E, Fernandes-Costa F: An outbreak of hepatitis A among South Africa patients with haemophilia: Evidence implicating contaminated factor VIII concentrate as the source. Hepatology 1995;22:1363-1367.
7. Wood DJ, Bird CR, Thorpe R, Barrowcliffe TW: Hepatitis A virus antibody levels in factor VIII concentrates. Lancet 1994;344:202.
8. Cunningham CJ: Preparation of factor IX concentrate for therapeutic use. Biochem Soc Trans 1981;9:326.
9. Middleton SM, Bennett IH, Smith JK: A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma. Vox Sang 1973;24:441-456.
10. Chandra S, Brummelhuis HGJ: Prothrombin complex concentrates for clinical use. Vox Sang 1981;41:257-273.
11. Aronson DL: Factor IX complex. Semin Thromb Haemost 1979;6:28-43.
12. Smith JJ, Bidwell E: Therapeutic materials used in the treatment of coagulation defects: Clin Haematol 1979;8:183-202.
13. Jarvis LM, Watson HG, McOmish F, Peutherer JF, Ludlam CA, Simmonds P: Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 1994;170:1018-1028.
14. McOmish F, Yap PL, Hart H, Peerlinck K, Bums SM, Simmonds P: Failure to detect hepatitis A virus RNA in factor VIII concentrates using the polymerase chain reaction. Vox Sang 1994;67(suppl 1):51-55.
15. Lemon SM, Murphy PC, Smith A, Zou J, Hammon J, Robinson S, Horowitz B: Removal/neutralisation of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate. J Med Virol 1994;4:44-49.
16. Hepatitis A among persons with haemophilia who received clotting factor concentrate. MMWR Morbid Mortal Wkly Rep 1996;45:1-6.
17. Tilzey AJ, Banatvala JE: Hepatitis A changing prevalance and possible vaccines (editorial). BMJ 1991;302:1552-1553.